JP2024507986A5 - - Google Patents
Info
- Publication number
- JP2024507986A5 JP2024507986A5 JP2023552183A JP2023552183A JP2024507986A5 JP 2024507986 A5 JP2024507986 A5 JP 2024507986A5 JP 2023552183 A JP2023552183 A JP 2023552183A JP 2023552183 A JP2023552183 A JP 2023552183A JP 2024507986 A5 JP2024507986 A5 JP 2024507986A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antibody fragment
- use according
- fragment
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21159860 | 2021-03-01 | ||
| EP21159860.2 | 2021-03-01 | ||
| PCT/EP2022/055080 WO2022184676A1 (en) | 2021-03-01 | 2022-03-01 | Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507986A JP2024507986A (ja) | 2024-02-21 |
| JP2024507986A5 true JP2024507986A5 (enExample) | 2025-03-07 |
Family
ID=74844778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023552183A Pending JP2024507986A (ja) | 2021-03-01 | 2022-03-01 | 抗体関連型移植拒絶反応の治療に使用するための抗ｃｄ３８抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240228654A9 (enExample) |
| EP (1) | EP4301779A1 (enExample) |
| JP (1) | JP2024507986A (enExample) |
| KR (1) | KR20230154239A (enExample) |
| AU (1) | AU2022230717A1 (enExample) |
| BR (1) | BR112023016352A2 (enExample) |
| CA (1) | CA3209172A1 (enExample) |
| CL (1) | CL2023002495A1 (enExample) |
| IL (1) | IL304692A (enExample) |
| MX (1) | MX2023009868A (enExample) |
| TW (1) | TW202302642A (enExample) |
| WO (1) | WO2022184676A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202545561A (zh) * | 2024-01-16 | 2025-12-01 | 德商莫菲西斯有限責任公司 | 抗體的高度濃縮液體製劑 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| WO1999062526A2 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| KR20140066259A (ko) | 2004-02-06 | 2014-05-30 | 모르포시스 아게 | 항-ｃｄ３８ 인간 항체 및 그의 용도 |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| WO2008037257A2 (en) | 2006-09-26 | 2008-04-03 | Genmab A/S | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| CN107406506A (zh) | 2014-12-04 | 2017-11-28 | 詹森生物科技公司 | 用于治疗急性髓系白血病的抗cd38抗体 |
| EA037548B1 (ru) | 2015-06-24 | 2021-04-12 | Янссен Байотек, Инк. | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3434692A1 (en) | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| US20220135695A1 (en) * | 2019-03-08 | 2022-05-05 | Cedars-Sinai Medical Center | Anti-cd38 agents for desensitization and treatment of antibody-mediated rejection of organ transplants |
| JP7687956B2 (ja) * | 2019-03-15 | 2025-06-03 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 |
-
2022
- 2022-02-25 TW TW111106934A patent/TW202302642A/zh unknown
- 2022-03-01 JP JP2023552183A patent/JP2024507986A/ja active Pending
- 2022-03-01 EP EP22708941.4A patent/EP4301779A1/en active Pending
- 2022-03-01 US US18/548,477 patent/US20240228654A9/en active Pending
- 2022-03-01 KR KR1020237033840A patent/KR20230154239A/ko active Pending
- 2022-03-01 MX MX2023009868A patent/MX2023009868A/es unknown
- 2022-03-01 AU AU2022230717A patent/AU2022230717A1/en active Pending
- 2022-03-01 BR BR112023016352A patent/BR112023016352A2/pt unknown
- 2022-03-01 CA CA3209172A patent/CA3209172A1/en active Pending
- 2022-03-01 WO PCT/EP2022/055080 patent/WO2022184676A1/en not_active Ceased
-
2023
- 2023-07-24 IL IL304692A patent/IL304692A/en unknown
- 2023-08-23 CL CL2023002495A patent/CL2023002495A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7771235B2 (ja) | 抗－ｃｄ１９抗体薬物複合体に関連する組成物および方法 | |
| JP2020019787A5 (enExample) | ||
| JP2022515077A5 (enExample) | ||
| BR112021005868A2 (pt) | Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g | |
| JP2020528768A5 (enExample) | ||
| BR112019016204A2 (pt) | anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d | |
| JP2021510736A5 (enExample) | ||
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| JP2021524256A5 (enExample) | ||
| TW202214697A (zh) | 抗ｃｄ７０抗體及其應用 | |
| JP2020536109A5 (enExample) | ||
| US9156912B2 (en) | Immunological reconstitution promoter or prophylactic agent for infections each of which maintains graft-versus-tumor effect | |
| JP2021527640A5 (enExample) | ||
| JP2024531151A5 (enExample) | ||
| JP2025183307A5 (enExample) | ||
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| JP2024520666A5 (enExample) | ||
| EP3842071A1 (en) | Use of tim-3 antibody in preparation of medicines for treating tumors | |
| JP2020513757A5 (enExample) | ||
| JP2024503784A5 (enExample) | ||
| JP2024540226A5 (enExample) | ||
| JP2024507986A5 (enExample) | ||
| US20210403573A1 (en) | Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells | |
| JP2024537284A5 (enExample) | ||
| JP2025509567A5 (enExample) |